Physician profile
Ron J Marek
NPI 1295701399
$1,524.37
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $440 · 2021: $207 · 2022: $107 · 2023: $42.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $42.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $42.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $702.52 | 2019-2023 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $119.03 | 2020 | |
| Astellas Pharma US INC | $99.99 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $83.63 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $64.77 | 2019-2021 | |
| Amgen INC. | $51.78 | 2019-2020 | |
| Allergan, INC. | $47.77 | 2019-2020 | |
| Lilly USA, LLC | $42.38 | 2020 | |
| Pfizer INC. | $40.90 | 2019-2020 | |
| Abbvie INC. | $36.01 | 2019-2022 | |
| Shire North American Group INC | $33.52 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $31.43 | 2020 | |
| Antares Pharma, INC. | $28.94 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $17.85 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.00 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $15.02 | 2019 | |
| Dermira, INC. | $14.92 | 2020 | |
| Merck Sharp & Dohme LLC | $13.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.53 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.11 | 2021 | |
| Amarin Pharma, INC. | $12.50 | 2019 | |
| Mylan Specialty L.P. | $12.10 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ron Marek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.